Nymox Pharmaceutical Corporation (NYMX): Price and Financial Metrics

Nymox Pharmaceutical Corporation (NYMX): $0.40

-0.02 (-3.65%)

POWR Rating

Component Grades













NYMX Stock Price Chart Interactive Chart >

Price chart for NYMX

NYMX Price/Volume Stats

Current price $0.40 52-week high $1.49
Prev. close $0.41 52-week low $0.19
Day low $0.36 Volume 35,700
Day high $0.41 Avg. volume 57,837
50-day MA $0.41 Dividend yield N/A
200-day MA $0.39 Market Cap 35.86M

Nymox Pharmaceutical Corporation (NYMX) Company Bio

Nymox Pharmaceutical Corporation engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer’s disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in Phase III clinical trials for the treatment of enlarged prostate or benign prostatic hyperplasia, as well as is in Phase II clinical trial for low grade localized prostate cancer. The company was founded in 1989 and is based in Nassau, The Bahamas.

NYMX Latest News Stream

Event/Time News Detail
Loading, please wait...

NYMX Latest Social Stream

Loading social stream, please wait...

View Full NYMX Social Stream

Latest NYMX News From Around the Web

Below are the latest news stories about NYMOX PHARMACEUTICAL CORP that investors may wish to consider to help them evaluate NYMX as an investment opportunity.

Nymox Announces Appointment of Christopher R. Riley as Chief Financial Officer

IRVINE, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce the appointment of Christopher R. Riley as Chief Financial Officer (CFO) of Nymox. Mr. Riley is a globally experienced executive and entrepreneur with many notable successes and has held major positions in large well known corporations. He was CFO for Frito-Lay Australia where he was in charge of the snack food division, and during his tenure he was key execut

Yahoo | March 21, 2023

Nymox Officially Granted Extension to Regain Listing Requirements

IRVINE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) has officially been granted by NASDAQ an additional period until July 3, 2023 to regain compliance with NASDAQ listing requirements, the Company reported today. Nymox has recently submitted its Market Approval Application (MAA) for the treatment of benign prostatic hyperplasia, prostate enlargement (BPH), in middle aged and elderly men, one of the most common disorders in the world.

Yahoo | March 15, 2023

One Nymox Pharmaceutical Corporation (NASDAQ:NYMX) insider upped their stake by 32% in the previous year

Insiders were net buyers of Nymox Pharmaceutical Corporation's ( NASDAQ:NYMX ) stock during the past year. That is...

Yahoo | March 6, 2023

Nymox Announces NYMOZARFEX Marketing Application is Accepted For Review

IRVINE, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce that the Company's recent submission of Fexapotide Triflutate for the treatment of symptoms of benign prostate enlargement (benign prostatic hyperplasia, referred to as BPH) has been validated by the Denmark authorities, and the formal review process has now started. The trademarked name for the new product is NYMOZARFEX (TM). The Marketing Authorization Applic

Yahoo | February 15, 2023

NYMOX Appeals Deficiency Letter

IRVINE, Calif., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) reports that on January 4, 2023 the Company received a deficiency letter from The Nasdaq Stock Market (“Nasdaq”) stating that, because the Company’s common stock continues to trade at less than $1.00 per share, the Company has not regained compliance with the Rule 5550(a)(2) requiring a minimum bid price, and because the Company’s Stockholders’ equity was less than $5,000,000 as of S

Yahoo | January 6, 2023

Read More 'NYMX' Stories Here

NYMX Price Returns

1-mo 1.63%
3-mo N/A
6-mo 0.00%
1-year -66.94%
3-year -81.31%
5-year -90.95%
YTD 23.72%
2022 -75.13%
2021 -47.58%
2020 12.73%
2019 67.94%
2018 -60.30%

Continue Researching NYMX

Here are a few links from around the web to help you further your research on Nymox Pharmaceutical Corp's stock as an investment opportunity:

Nymox Pharmaceutical Corp (NYMX) Stock Price | Nasdaq
Nymox Pharmaceutical Corp (NYMX) Stock Quote, History and News - Yahoo Finance
Nymox Pharmaceutical Corp (NYMX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7261 seconds.